CFM
EDIT icon

Catalyst Funds Management’s Editas Medicine EDIT Stock Holding History

Catalyst Funds Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,100
Closed -$48.1K – 607
2024
Q3 		$48.1K Buy
14,100
+3,100
+28% +$13.5K 0.01% 812
2024
Q2 		$51.4K Buy
11,000
+3,200
+41% +$18.1K 0.01% 413
2024
Q1 		$57.9K Buy
+7,800
New +$64.8K 0.02% 524

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Catalyst Funds Management's EDIT Position: Q4 2024 in Review

Catalyst Funds Management sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 14,100 shares — an estimated $48.1K sold.

Catalyst Funds Management first reported a position in EDIT in Q1 2024 and held it in 3 quarters. The position peaked at $57.9K in Q1 2024. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

  • Catalyst Funds Management reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 14,100 Editas Medicine shares in Q4 2024, an estimated $48.1K.
  • Catalyst Funds Management first reported a position in Editas Medicine in Q1 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Editas Medicine position peaked at $57.9K in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.